Home
This site is intended for healthcare professionals

Obstructive Sleep Apnea Care Pathways Translating Cardiometabolic Risk into Longitudinal Management: Module 1 Bidirectional pathophysiology

Share

Description

This activity is supported by an independent education grant from Lilly. This online education program has been designed for healthcare professionals in the U.S.

Join Dr. Virend Somers for a focused exploration of the cyclical relationship between obstructive sleep apnea (OSA) and cardiometabolic disease. This module details how intermittent hypoxia and sleep fragmentation trigger sympathetic activation, systemic inflammation, and oxidative stress, which directly exacerbate conditions like treatment-resistant hypertension and poorly controlled type 2 diabetes.

Session Highlights

  • Examine the bidirectional mechanisms where recurrent upper airway obstruction and intermittent hypoxia drive sympathetic activation, systemic inflammation, and oxidative stress.
  • Identify how untreated obstructive sleep apnea (OSA) exacerbates cardiometabolic conditions—including treatment-resistant hypertension, poorly controlled type 2 diabetes, and obesity—creating a self-reinforcing risk cycle.

Prefer to watch in Spanish? Click Here.

Who Should Participate?

This program is designed for healthcare professionals who seek to incorporate structured OSA screening and diagnostic activation into routine cardiometabolic management workflows.

  • Primary Care Physicians and Family Medicine Practitioners
  • Nurse Practitioners
  • Physician Assistants

This is Module One of Six, See Modules 2, 3, 4 5 and 6 Here.

Prefer to read? See our Key Clinical Summary Here.

Faculty

Dr Virend Somers

Dr Virend Somers is a Professor of Medicine and Consultant in Preventive Cardiology at Mayo Clinic, and a leading expert in sleep apnea and its cardiovascular consequences. His research focuses on the physiological mechanisms linking obstructive sleep apnea with cardiovascular disease, including changes in autonomic and vascular function, blood pressure, and heart failure. Through his work directing Mayo Clinic’s Sleep Facility, Dr Somers has contributed significantly to understanding how disordered sleep affects cardiovascular health, with a focus on translating these insights into improved recognition, management, and care for patients with sleep apnea.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr Virend Somers, faculty for this educational activity, has the following relevant financial relationships: Consultant Apnimed, GEM Med, Jazz Pharmaceuticals, Lilly.

The MedAll staff, program planners, and reviewers have no relevant financial relationships with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this live activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Associate Continuing Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information

There is no fee for this educational activity.

This continuing education activity is active starting September 11th 2026, and will expire on July 1st 2028.

Learning objectives

1: Evaluate the bidirectional relationship between obesity and OSA to inform cardiometabolic risk assessment, demonstrating accurate identification of OSA risk within ≥75% of post-activity case-based assessments.

2: Identify patients at increased risk of OSA using clinical features and comorbidities in primary care, achieving appropriate risk stratification in ≥75% of applied clinical scenarios.

3: Apply workflow-compatible screening and triage strategies to support early identification of OSA, demonstrating correct use of structured tools and decision pathways in ≥75% of simulation-based exercises.

4: Select appropriate diagnostic and referral pathways, including HSAT, based on clinical presentation and practice context, achieving appropriate pathway activation in ≥75% of case-based assessments.

5: Apply longitudinal management and treatment progression strategies in OSA care planning to support sustained disease control, demonstrating appropriate decision-making in ≥70% of longitudinal case exercises.

6: Apply contextually adapted care strategies that account for socioeconomic and practice-setting factors to support equitable diagnostic and management decisions in OSA, demonstrating appropriate decision-making in ≥70% of applied scenarios.

Similar communities

View all

Similar events and on demand videos

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

In this section we will cover the bidirectional pathophysiology of sleep apnea and metabolic disease. Here we see a schematic of sleep apnea driving cardio metabolic risk. The flow diagram on the right shows physiologic disruptions that occur in patients with obstructive sleep apnea. These include hypoxia and hypercapnia because of the prolonged apneas, repetitive arousals from sleep, and consequent sleep disruption. Now these events actually trigger a number of pathophysiological mechanisms. Some of which are listed here, the major one being sympathetic activation. Renin angiotensin aldosterone system activation, oxidative stress in large part because of the repetitive um hypoxemia and uh uh uh reoxygenation that occurs during apnea and systemic inflammation. A combination of all of these mechanisms result in end organ dysfunction, and this is manifest by endothelial dysfunction, insulin resistance, BP surges, and adipocyte dysfunction, all of which come to give you hypertension and or prediabetes or type 2 diabetes. The bidirectional loop between sleep apnea and obesity occurs because first, sleep apnea is a risk factor for obesity, diabetes, and cardiovascular disease, while evidence indicates, second, that metabolic disorders can themselves exacerbate OSA. So in terms of obesity causing obstructive sleep apnea, this is a well known phenomenon and is in Large part driven by an increased fat mass around the upper airway and in the belly, the consequent mechanical load, the narrowed airway, and potentially adipokines released from fat tissue that change respiratory balance and respiratory control. Now, sleep apnea causing obesity is a less well understood, but clearly, A real phenomenon because people with sleep apnea tend to put on a significant amount of weight just before they are diagnosed. So there's something about sleep apnea that seems to trigger an increase in obesity, and this may be in part due to sleep disruption causing increases in food intake, this resulting in weight gain. The also, uh, the other, uh, potential mechanism is somnolence in sleep apnea, leading to a potential increase in food intake. Now, in primary care, this loop is seen during hypertension follow-up, diabetes review, obesity care, and fatigue visits. And you should use these particular conditions as situations where you should consider patients having obstructive sleep apnea. Uh, if, if they have obesity in particular, or if they have daytime sleepiness, uh, in the context of sleep apnea. Now, which presentations trigger OSA assessment? If you see patients who present with pulmonary hypertension, nocturnal dysrhythmias, coronary artery disease, obesity, type 2 diabetes, heart failure, resistant or poorly controlled hypertension in particular, As well as atrial fibrillation that may occur uh after cardioversion or ablation, and in patients with prior strokes or repeated TIAs. Now, remember that sleep apnea can contribute to these conditions, so remember to ask about OSA in affected patients. Here's a patient case to illustrate a number of the concepts we've discussed. Mr. R is a 54-year-old diagnosed with type 2 diabetes and hypertension. His BMI is 38 kg per meter squared. He's got hypertension, which is uncontrolled on three agents, including a diuretic, despite documented adherence. His hemoglobin A1C has increased over the past year, despite stable metformin dosing. He reports feeling tired all the time and attributes it to work stress. Although his wife says that he does actually fall asleep in, in, in a number of different situations, including when watching TV when, um, uh, uh, uh, talking to her occasionally, and sometimes even feeling very drowsy when driving. Now, the decision rationale here is obesity with resistant hypertension and fatigue or daytime sleepiness. Should trigger a structured OSA risk assessment, and the action is to proceed to screening workflow rather than leaving OSA as a vague future consideration documented in the chart but not acted upon. So the clinical reasoning behind this flow is that You should not simply add a 4th antihypertensive before asking about sleep, because when you have a patient with resistant hypertension and evidence of potential sleep apnea, look for the presence of sleep apnea because treating the apnea can often help treat the hypertension. Now here's a polling question. How often do you currently consider sleep apnea when a patient presents with obesity, comorbid, with treatment resistant hypertension, or poorly controlled type 2 diabetes? Do you always consider that? Often, sometimes, rarely, or have you never ever thought of it? We'll give you time to answer. Now for a clinical pitfall, that fatigue equals lifestyle stress. Many patients present with fatigue and it's very easy to normalize it in busy adults and say, well, it's because of work, because of caregiving, because of chronic disease burden, and in patients with obesity, especially, type 2 diabetes, hypertension, or cardiovascular disease, persistent or unexplained fatigue, particularly if there's Uh, excessive daytime sleepiness should prompt consideration of obstructive sleep apnea. The wrong evaluation is to say that you're probably just exhausted and everyone feels tired when they're juggling work, family, and diabetes. The correct approach is that fatigue has many causes, but given your BP and diabetes, I also want to check whether sleep apnea could be contributing. Now, a list of practical tools that can trigger an evaluation for sleep apnea and cardio metabolic disease, consider OSA screening when any of the following are present. Resistant hypertension or repetitive escalation of anti-hypertensive therapy. Obesity plus difficult to control type 2 diabetes or worsening glycemic control. Obesity plus atrial fibrillation, recurrent arrhythmia or heart failure risk profile, obesity plus unexplained fatigue, sleepiness, morning headache, nocturia, or poor sleep quality, and any EHR prompt language that suggests that sleep apnea should be considered as a contributor to either hypertension, type 2 diabetes, or fatigue. In that case, screening is indicated. A summary checklist. Key practice points from this phase. Link obesity, obstructive sleep apnea, hypertension, and type 2 diabetes as a bidirectional risk cycle. Recognize resistant hypertension as a sleep apnea trigger. Recognize difficult to control type 2 diabetes as a sleep apnea trigger. Explain to a patient why sleep questions belong in cardio metabolic care. And last, document sleep apnea as a contributor to the presenting cardio metabolic issue.